Robert E. Landry - 10 Dec 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: EVP Finance CFO
Signature: /s/**Robert E. Landry
Issuer symbol: REGN
Transactions as of: 10 Dec 2021
Net transactions value: -$625,837
Form type: 4
Filing time: 14 Dec 2021, 15:03:50 UTC
Previous filing: 10 Dec 2021
Next filing: 18 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$833,505	+1,500	+5%	$555.67	31,457	10 Dec 2021	Direct	F1
transaction	REGN	Common Stock	Tax liability	$919,447	-1,384	-4.4%	$664.34	30,073	10 Dec 2021	Direct	F1
transaction	REGN	Common Stock	Tax liability	$463,045	-697	-2.3%	$664.34	29,376	11 Dec 2021	Direct
transaction	REGN	Common Stock	Sale	$76,850	-116	-0.39%	$662.50	29,260	13 Dec 2021	Direct	F1
holding	REGN	Common Stock						229	10 Dec 2021	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-1,500	-38%	$0.000000	2,500	10 Dec 2021	Common Stock	1,500	$555.67	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2	The stock option award vests in four equal annual installments, commencing one year after the date of grant.